Posted On: 04/06/2016 9:36:53 PM
Post# of 72446
My favorite part:
"Specifically, the Promise for Antibiotics and Therapeutics for Health (PATH) Act would allow the Food and Drug Administration (FDA) to approve antibiotics for limited populations of patients with serious and life-threatening bacterial infections that are resistant to current treatments — in other words, the types of antibiotics that could treat superbugs such as MCR-1 and others that will surely follow."
Let's see, MRSA is a superbug and there'll be an interim analysis. I'm sure Leo will apply for the "limited-population antibacterial drugs" approval pathway if the interim analysis is positive.
"Specifically, the Promise for Antibiotics and Therapeutics for Health (PATH) Act would allow the Food and Drug Administration (FDA) to approve antibiotics for limited populations of patients with serious and life-threatening bacterial infections that are resistant to current treatments — in other words, the types of antibiotics that could treat superbugs such as MCR-1 and others that will surely follow."
Let's see, MRSA is a superbug and there'll be an interim analysis. I'm sure Leo will apply for the "limited-population antibacterial drugs" approval pathway if the interim analysis is positive.
(0)
(0)
